Achilles Therapeutics Plc - ADR

-0.09 (-1.79%)
Products, Strategic Combinations

Secarna Pharmaceuticals And Achilles Therapeutics Sign Research Agreement To Develop Optimized T Cell Therapies

Published: 11/10/2021 13:06 GMT
Achilles Therapeutics Plc - ADR (ACHL) - Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies.
Under Terms of Agreement, Secarna Will Receive an Undisclosed Upfront Payment, a Target-based Technology Access Fee As Well As Option Exercise Fees.
Secarna is Also Eligible to Receive Development and Commercial Milestone Payments As Well As Tiered Royalties on Net Sales of Personalized T Cell Therapies Developed and Commercialized Under This Collaboration.